Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
NCT06489249Phase 1Recruiting
- Sponsor
- University of Iowa
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Amigesic in endothelial dysfunction (2 arms), sponsored by University of Iowa. Primary endpoint: Microvascular endothelial function at 4 days. Started Aug 2024; status: recruiting.
02
Drugs
Amigesic
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT06489249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489249.